127,567 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Acquired by Tri Locum Partners LP

Tri Locum Partners LP acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,567 shares of the company's stock, valued at approximately $9,805,000. GeneDx comprises about 2.0% of Tri Locum Partners LP's investment portfolio, making the stock its 20th biggest position. Tri Locum Partners LP owned 0.46% of GeneDx as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC increased its stake in shares of GeneDx by 346.3% during the 3rd quarter. Barclays PLC now owns 18,921 shares of the company's stock worth $803,000 after purchasing an additional 14,681 shares in the last quarter. Franklin Resources Inc. purchased a new position in GeneDx during the third quarter worth $301,000. Prudential Financial Inc. acquired a new position in shares of GeneDx in the fourth quarter worth $7,938,000. JPMorgan Chase & Co. lifted its position in shares of GeneDx by 617.3% in the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company's stock valued at $2,214,000 after acquiring an additional 44,889 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in shares of GeneDx during the third quarter valued at $604,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 1,657 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total value of $130,041.36. Following the transaction, the chief executive officer now owns 3,937 shares in the company, valued at $308,975.76. The trade was a 29.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.72, for a total value of $87,331.84. Following the sale, the chief financial officer now owns 5,446 shares of the company's stock, valued at $515,845.12. This represents a 14.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 138,780 shares of company stock valued at $12,907,437 over the last three months. 27.30% of the stock is owned by company insiders.

GeneDx Stock Performance

Shares of WGS stock opened at $111.01 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -56.64 and a beta of 1.93. GeneDx Holdings Corp. has a one year low of $10.70 and a one year high of $115.60. The company has a 50 day moving average price of $95.78 and a 200 day moving average price of $81.81.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on WGS shares. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group upped their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, GeneDx currently has an average rating of "Moderate Buy" and a consensus price target of $72.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.